Stockscreener 앱 받기
4.36
7.39%
0.30
전일 마감가:
$4.06
열려 있는:
$4.12
하루 거래량:
611.14K
Relative Volume:
0.59
시가총액:
$319.73M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-1.3333
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
+4.56%
1개월 성능:
+10.38%
6개월 성능:
+522.68%
1년 성능:
+1,088%
1일 변동 폭
$4.01
$4.45
1주일 범위
$3.995
$4.72
52주 변동 폭
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.17 | 303.77M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.04 | 221.34M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.67 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.76 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser
How supply chain issues affect Relmada Therapeutics Inc. stockQuarterly Earnings Report & Long-Term Growth Plans - moha.gov.vn
Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada
Relmada Therapeutics Announces $100 Million Underwritten Offering - globallegalchronicle.com
Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in
Pullback Watch: Is Relmada Therapeutics Inc. stock supported by innovation pipelineWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flows - BỘ NỘI VỤ
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content
Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN
Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com Nigeria
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com
What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com
Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus
Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus
Relmada Therapeutics upgraded by Mizuho with a new price target - Quantisnow
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
0.36%
1.12%
자본화:
|
볼륨(24시간):